Abstract: An input-output data collector collects, from a programmable logic controller, input-output data representing a log for a device in a program predetermined as a logging target program of one or more programs executable by the programmable logic controller. An input-output data generator generates, when a debugging target program is determined not to be included in the predetermined program, input-output data representing a log for a device in the debugging target program by executing a simulation program simulating an operation of the programmable logic controller.

Abstract: A processor synthesis device inserts a stop circuit into a circuit configuration, which is defined by processor model information and includes a plurality of operators, based on instruction set information that defines an instruction set including a plurality of instructions, the stop circuit stopping an operator not used in an instruction to be executed among the plurality of operators when each of the plurality of instructions is executed. The processor synthesis device generates processor synthesis information which is an RTL description defining a circuit configuration into which the stop circuit is inserted.

Abstract: A processor synthesis device inserts a stop circuit into a circuit configuration, which is defined by processor model information and includes a plurality of operators, based on instruction set information that defines an instruction set including a plurality of instructions, the stop circuit stopping an operator not used in an instruction to be executed among the plurality of operators when each of the plurality of instructions is executed. The processor synthesis device generates processor synthesis information which is an RTL description defining a circuit configuration into which the stop circuit is inserted.

Abstract: A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi.

Abstract: In one embodiment, there is provided a fuel cell evaluator for evaluating a characteristic of a fuel cell based on a frequency characteristic of impedance of the fuel cell. The evaluator includes: an impedance acquisition unit configured to acquire impedances of the fuel cell for a certain current value in a Tafel region by changing a measurement frequency; an extraction unit configured to extract a reaction resistance from the acquired impedances; a calculator configured to calculate the product of the reaction resistance and the certain current value; and an indicator configured to indicate the product calculated by the calculator as the frequency characteristic of the impedance of the fuel cell.

Abstract: A method for determining response characteristics of a battery includes: pressurizing the battery in a direction to reduce a distance between electrode surfaces of the battery; and applying a voltage or a current to the pressurized battery to determine response characteristics of the battery.

Abstract: A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi.

Abstract: A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi.

Abstract: An electrode evaluation apparatus for evaluating a characteristic of an electrode based on an electrochemical property includes a potential control unit, an impedance acquiring unit, a current value acquiring unit, and a normalized impedance calculation unit. The potential control unit is configured to control a potential applied to an electrode. The impedance acquiring unit is configured to acquire an impedance characteristic of the electrode under a specific DC operating condition provided by the potential control unit. The current value acquiring unit is configured to acquire a temporal change in direct current value under the specific DC operating condition. The normalized impedance calculation unit is configured to apply the temporal change in direct current value acquired by the current value acquiring unit to calculate a normalized impedance where impedance acquired by the impedance acquiring unit is multiplied by the direct current value.

Abstract: By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.

Abstract: There is provided a secondary battery tester for testing a state of a secondary battery based on an impedance characteristic of the secondary battery. The tester includes: an impedance acquiring section configured to acquire an impedance value of the secondary battery; and a determining section configured to determine a state of a solid electrolyte interface (SEI) layer of the secondary battery based on the impedance value acquired by the impedance acquiring section.

Abstract: By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.

Abstract: By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.

Abstract: A method for determining response characteristics of a battery includes: pressurizing the battery in a direction to reduce a distance between electrode surfaces of the battery; and applying a voltage or a current to the pressurized battery to determine response characteristics of the battery.

Abstract: A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi.

Abstract: Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-?. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-? production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.

Abstract: There is provided a secondary battery tester for testing a state of a secondary battery based on an impedance characteristic of the secondary battery. The tester includes: an impedance acquiring section configured to acquire an impedance value of the secondary battery; and a determining section configured to determine a state of a solid electrolyte interface (SEI) layer of the secondary battery based on the impedance value acquired by the impedance acquiring section.

Abstract: In one embodiment, there is provided a fuel cell evaluator for evaluating a characteristic of a fuel cell based on a frequency characteristic of impedance of the fuel cell. The evaluator includes: an impedance acquisition unit configured to acquire impedances of the fuel cell for a certain current value in a Tafel region by changing a measurement frequency; an extraction unit configured to extract a reaction resistance from the acquired impedances; a calculator configured to calculate the product of the reaction resistance and the certain current value; and an indicator configured to indicate the product calculated by the calculator as the frequency characteristic of the impedance of the fuel cell.

Abstract: Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-?. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-? production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.

Abstract: A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi.